AMENDMENTS TO THE CLAIMS

1. (**Currently amended**)A stable and soluble ~~P~~pharmaceutical composition ~~characterized by~~ comprising:

(a) ~~a therapeutic amount of the protease inhibitor [5S-(5R*,8R*,10R*,11R*)]-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid 5-thiazolylmethyl ester (~~ritonavir~~)~~ employed in an amount ranging from 1.0% to 50% in weight of the final composition;

(b) a mixture of alcoholic solvent and alcoholic co-solvent ~~from~~ of C_2-C_4 which are employed in total amount ranging from 10% to 30% in weight of the final composition;

(c) a mixture of C_8-C_{10} medium chain mono/diglycerides ~~of C_8-C_{10}~~ employed in an amount ranging from 20% to 70% in weight of the final composition;

(d) a pharmaceutical suitable surfactant employed in an amount ranging from 0.1% to 20% in weight of the final composition;

(e) an antioxidant employed in an amount ranging from 0.001% to 2.0% in weight of the final composition.

2. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim 1, ~~characterized by~~ which optionally ~~comprising~~ further comprises:

(a1) an emulsion ~~stabilizer~~-stabilizing agent employed in an amount ranging up to 60% in weight of the final composition;

(b1) a polarity corrector agent employed in an amount up to 0.5% in weight of the final composition.

3. (**Canceled**)

4. (**Canceled**)

5. (**Canceled**)

6. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim ~~5~~ 1, ~~characterized by~~ wherein the alcoholic solvent is used in a concentration ranging from 5.0% to 15% in weight of the final composition.

7. (**Canceled**)

8. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim ~~7~~ 1, ~~characterized by~~ wherein the alcoholic co-solvent is used in a concentration ranging from 5.0 to 15% in weight of the final composition.

9. (**Canceled**)
10. (**Canceled**)
11. (**Canceled**)
12. (**Canceled**)
13. (**Canceled**)
14. (**Canceled**)

15. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim 1, ~~characterized by~~ wherein the alcoholic solvent is ethanol and the alcoholic co-solvent is propylene glycol.

16. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim 1, ~~characterized by~~ wherein the surfactant is polyethoxylated castor oil 35, and/or hydrogenated polyethoxylated castor oil 40, and/or polysorbates 20, 40, 60 or 80.

17. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim 1, ~~characterized by~~ wherein the antioxidant is butylated hydroxy toluene and/or alpha-tocopherol.

18. (**Canceled**)

19. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim ~~1 or~~ 2, ~~characterized by~~ wherein the emulsion-stabilizing agent is polyethylene glycol 400 (PEG 400).

20. (**Canceled**)

21. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim ~~1 or~~ 2, ~~characterized by~~ wherein the polarity corrector agent is citric acid and/or ascorbic acid.

22. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with ~~any one of~~ claim~~s~~ 1~~-21~~, ~~characterized by being~~ which is employed for oral administration as an oral solution, hard gelatin capsules and/or soft gelatin capsules.

23. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with claim 22, ~~characterized by being~~ which is employed for oral administration as soft gelatin capsules.

24. (**Currently amended**)The ~~P~~pharmaceutical composition in accordance with ~~any one of~~ claim~~s~~ 1~~-21~~, ~~characterized by being~~ which is employed in the treatment of viral infections;

25. (**Currently amended**)The ~~P~~pharmaceutical compositions in accordance with ~~any one of~~ claims 1~~-21~~, ~~characterized by being~~ which is employed in medicine or veterinary;

26. (**Currently amended**)Process for preparing the soluble, stable, and concentrated pharmaceutical compositions of ~~[5S-(5R*, 8R*, 10R*, 11R*)]-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3, 6-dioxo-8, 11-bis(phenylmethyl)-2, 4, 7, 12-tetraazatridecan-13-oic acid 5-thiazolylmethyl ester (~~ritonavir~~),~~ of claim 1 comprising the following steps:

(a2) dissolving ~~[5S-(5R*, 8R*, 10R*, 11R*)]-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3, 6-dioxo-8, 11-bis(phenylmethyl)-2, 4, 7, 12-tetraazatridecan-13-oic acid 5-thiazolylmethyl ester (~~ritonavir~~)~~, in ~~a sufficient amount of~~ an alcoholic solvent of C_2-C_4, under controlled temperature to make a first mixture;

(b2) eliminating solid particles from said first mixture by filtration;

(c2) evaporating the alcoholic solvent from said filtered first mixture ~~,~~ under reduced pressure at low temperature to about half of its initial concentration;

(d2) adding to said filtered and concentrated first mixture an alcoholic co-solvent, a medium chain mono/diglycerides mixture, an antioxidant, an emulsion-stabilizing agent and a polarity corrector to make a second mixture ~~in the appropriate amounts for the composition~~;

(e2) removing the alcoholic solvent of step (a2) from said second mixture by distilling under reduced pressure ~~until the remaining quantity is the desired quantity in the composition~~;

(f2) adding to said distilled second mixture ~~the~~ a surfactant under continuous stirring, ~~and keeping stirring~~ until said surfactant added to said distilled second ~~complete~~ mixture becomes a clear solution, thereby obtaining a soluble stable and concentrated ritonavir pharmaceutical composition; ~~,~~ and

(g2) correcting the ~~composition~~ final weight of said pharmaceutical composition by adding the alcoholic solvent employed in the ~~initial dissolution of ritonavir~~ step (a2)~~,if necessary~~.

27. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the alcoholic solvent used in (a2) is ethanol.

28. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the step (a2) is conducted in a temperature ranging from 30° C to 45°C.

29. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the step (c2) is conducted at a maximum temperature of 40°C.

30. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the co-solvent employed in step (d2) is propylene glycol.

31. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the medium chain mono/diglycerides employed in step (d2) is a mixture of C_8-C_{10} medium chain mono/diglycerides ~~of C_8-C_{10}~~.

32. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the antioxidant employed in step (d2) is butylated hydroxy toluene or alpha-tocopherol.

33. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the emulsion-stabilizing agent employed in step (d2) is polyethylene glycol 400 (PEG 400).

34. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the polarity corrector is citric acid or ascorbic acid.

35. (**Currently amended**)The ~~P~~process in accordance with claim 26, ~~characterized by~~ wherein the surfactant is polyethoxylated castor oil 35, and/or polyethoxylated hydrogenated castor oil 40, and/or polysorbates 20, 40, 60 or 80.

36. (**Canceled**)